CULGenesis — A Cornell-Origin Platform for Genomic Skin Resilience

01 · We Are CULGenesis

A biological platform closing the Genomic Repair Gap.

Sunscreen and barrier care have protected the surface of the skin for fifty years. But environmental exposure has changed faster than topical protection can compensate — and the genomic damage that drives aging, inflammation, and disease accumulates underneath.

CULGenesis is the next layer.

Our patented small molecules are designed to preserve effective lesion-recognition capacity during the extended post-exposure period — supporting the skin's endogenous CUL4-regulated NER machinery as it identifies and resolves persistent UV photolesions. Protection becomes repair. Repair becomes resilience.

Built on Cornell-origin science. Our composition-of-matter intellectual property is exclusively licensed from Cornell University.

// Three Pillars

What we're building.

▲ Topical · 2027

From Protection to Repair

The first topical products launch in 2027 — generating high-margin revenue from day one, proving the science in market, and funding everything that follows.

▲ Pipeline · 2028+

Beyond the Skin

Skin is the initial program. The same regulatory biology may extend to other epithelial interfaces — a longer-range platform hypothesis we'll validate as data accumulates.

▲ IP · Cornell

Patented Composition-of-Matter

Exclusively licensed from Cornell University. Foundational research established the CUL4A regulatory role in UV-damage response; the licensed chemistry is the proprietary CULGenesis advance.

▲ Design Commitment

Built for the full spectrum of human skin.

UV-associated DNA lesions occur across skin tones, and visible burn is not a universal indicator of underlying damage. Pigmentation also shapes the kinetics of post-exposure lesion formation. CULGenesis intends to validate performance across objective melanin levels and diverse phototypes — not as a marketing claim, but as a development principle baked into study design.

02 · The Dark Repair Gap

The sun sets before the damage does.

Sun exposure activates melanin chemiexcitation — a slow chemical reaction that can continue generating potentially mutagenic DNA lesions for hours after the last photon arrives. At the same time, lesion-recognition proteins are subject to tightly timed turnover. This creates the Dark Repair Gap: a potential mismatch between lesion burden and available repair capacity.

Protection addresses the moment of exposure.
Repair must operate on the window that follows.

▲ A Complementary Layer

Conventional photoprotection is designed for the moment of exposure — filtering radiation as it arrives. Chemiexcitation operates on a different timescale: lesion formation can continue past sunset. CULGenesis is designed as the complementary post-exposure layer — supporting endogenous repair after the protection layer has done its work.

17×

Melanoma rising in men more than 17× faster today than in the 1950s — despite five decades of SPF.

▲ Source · JAMA Dermatology / SEER trend data

300^%

Non-melanoma skin cancers increased by more than 300% globally in the modern environmental era.

▲ Source · WHO IARC, Global Cancer Observatory

Hours

Dark CPD-class lesions continue forming after UV exposure ends. In experimental melanocyte systems, a substantial fraction of measured CPDs formed after irradiation had stopped — driven by chemiexcitation, not photons.

▲ Source · Premi et al., Science 2015 · Brash lab, Yale

◆ Mechanism · The Kinetic Mismatch

Lesion creation can outlast the recognition window.

Nucleotide Excision Repair (NER) removes UV photoproducts and a range of bulky, helix-distorting chemical lesions. Damage detection involves the CRL4-DDB2 ubiquitin ligase and XPC recognition complex; the sequence requires orderly handoff.

Delayed lesions may continue emerging while these early recognition proteins undergo tightly timed turnover — creating a potential mismatch between lesion burden and available repair capacity.

Over years, unrepaired damage may accumulate into a backlog of genomic injury — associated with premature aging, immune dysregulation, and elevated skin-cancer risk.

// The Dark Repair Gap Delayed lesions may remain while early recognition capacity is contracting

● CONCEPTUAL MODEL

▲ Platform Thesis CULGenesis is designed to preserve effective lesion-recognition capacity through the extended post-exposure period — supporting the cell's native repair sequence without disabling the coordinated handoff required for complete NER.

▲ Evidence Status Conceptual model informed by published biology. Compound-specific kinetics and study details available under confidentiality.

03 · The Platform

Mechanism-defined.
Patented. Validated.

Many cosmetic ingredients are selected primarily for phenotype-level benefits. CULGenesis begins with a defined molecular target, measurable pathway engagement, and composition-of-matter chemistry — the foundation for defensible claims, fortified IP, and a credible development program.

NER is the repair engine. CUL4A is the regulatory checkpoint — the scaffold that helps govern timing, availability, and handoff of early lesion-recognition proteins. Our patented small molecules are designed to tune that checkpoint — supporting endogenous repair capacity through the post-exposure window without disrupting the orderly handoff NER completion requires.

// 01Defensible Claims

// 02Fortified IP

// 03Platform Extension

The regulator, not the engine

NER is the body's DNA repair engine. CUL4A is the molecular governor — the regulatory scaffold of the CRL4-DDB2 ubiquitin ligase complex that determines how long lesion-recognition capacity remains available. We modulate the governor, not the engine.

Tune the regulatory checkpoint

Our actives are designed to support repair-recognition capacity through the post-exposure period — when chemiexcitation may continue seeding potentially mutagenic lesions after exposure ends — without disrupting the orderly handoff that NER completion requires.

▲ Technical · CULGenesis compounds are designed to modulate CUL4-dependent regulation of early lesion-recognition machinery — including the DDB2–XPC axis involved in global-genome NER.

Two Nobel-recognized domains

The mechanism sits at the convergence of ubiquitin-mediated regulation (2004) and nucleotide excision repair (2015) — published in peer-reviewed literature.

Cosmetic regulatory framework

The initial topical program is being developed for commercialization within the US cosmetic regulatory framework — including applicable MoCRA requirements. Therapeutic applications would follow the corresponding drug-development requirements.

SAFETY · 01

Non-Cytotoxic

Lead-compound preclinical testing across primary keratinocyte and fibroblast models.

SAFETY · 02

AMES-Negative

Lead-compound result via standard genotoxicity panel.

SAFETY · 03

Non-Phototoxic

Lead-compound testing under direct UV exposure conditions.

CLINICAL · CONTROLLED

Lesion Clearance ↑

Controlled clinical evidence — a vehicle-controlled study showing post-exposure erythema reduction attributable to the active. Full design and results available under confidentiality.

04 · Where We Sit

A differentiated upstream layer.

SPF filters initiating radiation. Senolytics address senescent cells once they form. NAD+ boosters support cellular energetics. CULGenesis is designed to operate further upstream — supporting endogenous repair of the genomic damage that precedes downstream pathology. Designed as a complementary layer, not a replacement for existing interventions.

← Upstream · Cause Downstream · Symptom →

Stage 00 · Pre-Exposure Protection First layer · operating before exposure

◆ SPF

Designed for the moment of exposure — filters initiating UV radiation. Operates on a different timescale than chemiexcitation, which can continue producing potentially mutagenic lesions after exposure ends. CULGenesis is positioned as the complementary post-exposure layer.

↓ Persistent
lesions extend
into Stage 01

Stage 01 · Root Cause

Genomic Damage Event

Unrepaired DNA lesions from UV, pollution, oxidative stress, and chemical mutagens accumulate in the cell — the substrate every downstream pathology builds on.

Intervention · DNA Repair Modulation

◆ CULGenesis

Mechanism-defined small-molecule platform · differentiated approach

Stage 02 · Hallmark

Senescent-Cell Accumulation

Damaged cells exit the cycle, persist in tissue, and secrete inflammatory SASP signals that propagate dysfunction to neighbors.

Intervention · Senolytics

Unity Biotech · Rubedo · Fisetin (D+Q)

Clears the damage after it forms

Stage 03 · Hallmark

Mitochondrial Dysfunction

Energy production declines, ROS rises, repair capacity drops further — accelerating the cycle of accumulating damage in surviving cells.

Intervention · NAD+ / Energetics

Elysium · Tru Niagen · Timeline (Urolithin A)

Rescues energy after it declines

Stage 04 · Surface

Phenotype · Visible Aging

Wrinkles, hyperpigmentation, barrier loss, photoaging, elevated skin-cancer risk — what's seen in the mirror is the end of the cascade.

Intervention · Topical Actives · SPF

SPF · Retinoids · Peptides · Antioxidants

Treats the symptom at the surface

05 · Evidence Architecture

What's established. What's licensed. What we've measured. What we're testing.

Investor-grade science requires explicit confidence boundaries. The following maps every claim on this site to its source: established literature, the Cornell-licensed chemistry and IP estate, the internal datasets CULGenesis has generated, and the hypotheses now being validated. Detailed methods, results, and patent specifics are available under confidentiality.

// 01 External · Peer-Reviewed

Established by literature.

Melanin chemiexcitation — delayed CPD formation post-exposure · Premi et al., Science 2015 (Brash lab, Yale)
Nucleotide Excision Repair mechanism · 2015 Nobel Prize in Chemistry
Ubiquitin-mediated regulation of cellular processes · 2004 Nobel Prize in Chemistry
CUL4A regulatory role in UV-damage response and skin carcinogenesis · Molecular Cell, peer-reviewed literature
Hallmarks of Aging framework, genomic instability as primary hallmark · López-Otín et al., Cell 2013 / 2023

◆ Settled science

// 02 Proprietary · Cornell-Licensed

Exclusively licensed.

Composition-of-matter chemistry targeting CUL4A regulatory function · Cornell University, exclusively licensed to CULGenesis
Mechanism-defined compound class binding CUL4-dependent regulatory machinery · Method-of-action patents in estate
Rational compound development against the characterized regulatory target · CULGenesis pipeline
Patent estate covering composition and mechanism · Patent numbers, license scope, and field/territory by inquiry

◆ Cornell-licensed IP estate

// 03 Internal · Preclinical + Clinical

CULGenesis datasets.

Lead-compound safety panel — non-cytotoxic across primary keratinocyte and fibroblast models
AMES-negative by standard genotoxicity panel
Non-phototoxic under direct UV exposure conditions
Controlled clinical evidence — a vehicle-controlled study showing post-exposure erythema reduction attributable to the active; full results available under confidentiality
Full study designs, methods, statistical detail, contract-lab references, and provenance available by inquiry under confidentiality

◆ Internal datasets · by inquiry

// 04 Contextual Substantiation

Sharpening the claim.

Efficacy, mechanism, and safety are demonstrated. This work determines how specific and exclusive the post-exposure claims can be — claim architecture, not proof of concept.

Chemiexcitation × CUL4A context — extending demonstrated CPD-reduction and repair-support activity specifically into the delayed dark-CPD window
Time-course studies in pigmented melanocyte and reconstructed-skin systems
Pigmentation-stratified validation across the full range of skin tones
Dose-response and formulation persistence across the post-exposure window

◆ In progress · claim architecture & category ownership

▲ Long-Range Platform Opportunities Ingestible and inhalable formulations across other epithelial interfaces remain platform hypotheses pending future preclinical and IND-enabling work — not near-term commitments.

▲ Investor Diligence A confidential data room with patent filings, license documentation, preclinical study reports, contract-lab reference, vehicle-controlled clinical study design and statistical results, and regulatory-counsel opinion is available to qualified investors and strategic partners under NDA.

06 · Roadmap · Skin First

One regulatory insight. A platform beginning with skin.

The initial program is dermatologic — a topical AM/PM system addressing the post-exposure repair window. The same CUL4-regulated biology may extend to other epithelial interfaces over time, but those longer-range opportunities remain platform hypotheses we will validate as data accumulates.

// Two Products · One Mechanism

Aligned to the kinetic biology.

The portfolio is designed to mirror the mechanism. Morning supports recognition capacity ahead of exposure; evening supports the regulatory checkpoint through the post-exposure window in which chemiexcitation may continue producing potentially mutagenic lesions. An AM/PM ritual aligned to the kinetic biology of DNA damage.

AM Pre-Exposure Priming

Solar Prime

Primes the CRL4-DDB2 recognition complex before exposure. Sets repair capacity for the day ahead.

▲ Morning Application

Walk into the day prepared. Repair-recognition capacity primed for the exposure window ahead.

PM Post-Exposure Sustaining

Signal Mist

Sustains the regulatory checkpoint through the dark-CPD window. Extends recognition through the hours when chemiexcitation continues to seed lesions.

▲ Evening Application

The sun has set. The lesion field has not. Let the cell finish what exposure began.

▲ Why this matters Conventional photoprotection is designed for the moment of exposure. Chemiexcitation extends the lesion timeline past it. CULGenesis introduces a product architecture aligned to the full temporal arc of DNA damage — complementary to existing protection.

// Three Interfaces · One Closed Loop ● PLATFORM

▲ Why this matters Most interventions in DNA-repair and longevity biology operate downstream of damage. CULGenesis is a differentiated, mechanism-defined small-molecule platform positioned upstream — beginning with skin, with the regulatory biology potentially extending to other epithelia over time.

// Execution Sequence

Sequenced delivery.

2025–2026

Validation

Pilot trials · IP fortified · Series A close

2027

Topical Launch

First SKUs under MoCRA · revenue from day one

Mid-range

Ingestible

Platform hypothesis · pending data

Long-range

Inhalable

Therapeutic opportunity · IND-enabling work required

07 · The Team

Cornell-origin science meets operator-led commercialization.

The founding team unites the scientist whose foundational research established CUL4A as a regulator of the DNA-damage response with a multi-cycle biotech operator. Extended team, advisors, and detailed CVs available by inquiry.

▲ CEO · Founder

Paul Mola

Chief Executive Officer

Biotechnology entrepreneur and commercialization leader with more than 30 years translating breakthrough science into scalable companies and global markets.

Paul previously founded and led Roswell Biotechnologies, advancing the world's first molecular-electronics platform for DNA analysis. He has held senior leadership roles at Life Technologies and Roche Diagnostics across strategy, genomics, commercial operations, and institutional partnerships.

▲ At CULGenesis Corporate strategy, financing, platform development, commercialization

▲ CSO · Co-Founder

Dr. Pengbo Zhou

Chief Science Officer

A molecular biologist whose foundational research helped establish CUL4A as a critical regulator of the DNA-damage response and nucleotide excision repair.

As a faculty scientist at Cornell University, Dr. Zhou led research defining how CUL4A-dependent ubiquitin signaling controls damage recognition, protein turnover, cell-cycle checkpoints, and the cellular response to ultraviolet injury — work that provided the scientific foundation for the CULGenesis platform and the composition-of-matter IP licensed from Cornell.

Author of more than 20 peer-reviewed publications spanning ubiquitin-ligase biology, DNA repair, cancer biology, and therapeutic target discovery.

▲ At CULGenesis Scientific strategy, mechanism validation, compound development

▲ Advisor · Board

Xi Qin

Advisory & Board Member

Deep experience in regulatory strategy, translational science, and institutional collaborations.

Guides scientific integrity, preclinical roadmap, and board-level governance for the CULGenesis program.

▲ At CULGenesis Scientific integrity · Preclinical roadmap · Board governance

◆ Extended team, advisors, and detailed CVs available by inquiry under confidentiality

08 · For Investors

Cornell-origin science. Differentiated small-molecule platform.

Series A open. The 2027 topical program is the initial commercial milestone. The same CUL4-regulated biology may extend to other epithelial interfaces over time — longer-range platform opportunities pending validation.

RoundSeries A · open
HQSan Francisco, CA · Northern California venture
IPComposition-of-matter · Cornell-licensed
MechanismCUL4A modulation · CUL4-regulated NER
First Revenue2027 — Topical · cosmetic framework
ExpansionOther epithelia · long-range hypothesis
ValidationLead compound preclinical safety panel · vehicle-controlled clinical study

● Now Open

Series A Investor Materials

Request our deck, IP summary, pilot data overview, and commercialization plan. Conversations welcome with strategic partners and category-defining capital.

Request Materials →

09 · Investor FAQ

Questions diligence will ask.

Pre-empted, not deflected. Detailed answers in the deck — these are the lines.

// 01 Why a platform, not a single product?

CUL4-regulated NER biology is the core mechanism — initially developed for skin. The same regulatory insight may extend to other epithelial tissues where CUL4-dependent repair biology is relevant, but those are platform hypotheses pending validation. Initial program: topical. Longer-range opportunities follow data. The same composition-of-matter IP underwrites the family.

// 02 What's the regulatory risk?

The initial topical program is being developed for commercialization within the US cosmetic regulatory framework, including applicable MoCRA requirements. Product claims and intended use are being shaped with regulatory counsel to remain appropriate to that framework. Therapeutic applications (ingestible or inhaled) would follow the corresponding drug-development requirements — a long-range opportunity, not a near-term claim.

// 03 How defensible is the IP beyond the licensed molecule?

Composition-of-matter on the lead chemistry, exclusively licensed from Cornell. Mechanism patents around CUL4A-binding chemistry provide a second layer of protection. Mechanism-defined chemistry supports rational development of next-generation compounds against the characterized regulatory target. Full patent numbers and license scope available under confidentiality.

// 04 What's the moat after the first SKU?

Subsequent topical formulations extend the dermatologic franchise — same mechanism, different formulations, mechanism-protected IP. Longer-range opportunities in other epithelial interfaces remain platform hypotheses pending validation. The launch generates revenue and brand recognition while platform development continues.

// 05 How does this compare to other DNA-repair / longevity companies?

Most operate downstream of damage — senolytics address senescent cells once they form; NAD+ boosters support cellular energetics. CULGenesis is a differentiated small-molecule platform positioned upstream, supporting endogenous repair capacity at the genomic-damage event itself. Same Hallmarks-of-Aging map. Different intervention point. Detailed cascade comparison in Section 04.

// 06 Why this category, why now? What about chemiexcitation?

In 2015, Premi et al. (Brash lab, Yale) demonstrated that melanin chemiexcitation can continue generating CPD-class DNA lesions for hours after UV exposure ends. The category implication: photoprotection addresses the moment of exposure; the lesion timeline can extend beyond it.

CULGenesis is developing a differentiated small-molecule approach for what follows exposure — designed to support endogenous CUL4-regulated NER capacity rather than relying solely on radiation filtering or antioxidant defense. The portfolio architecture (Solar Prime AM / Signal Mist PM) is aligned to that temporal biology.

We position this as a complementary category: Post-Exposure DNA Repair. Sunscreen reduces initiating radiation. CULGenesis supports the cell's capacity to resolve lesions afterward.

▲ Deeper diligence answered in the deck — request below.